Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium.

doi:10.1038/s41598-021-99496-2

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium.

Scientific reports - 7 Oct 2021

Boemer François, Caberg Jean-Hubert, Beckers Pablo, Dideberg Vinciane, di Fiore Samantha, Bours Vincent, Marie Sandrine, Dewulf Joseph, Marcelis Lionel, Deconinck Nicolas, Daron Aurore, Blasco-Perez Laura, Tizzano Eduardo, Hiligsmann Mickaël, Lombet Jacques, Pereira Tatiana, Lopez-Granados Lucia, Shalchian-Tehran Sarvnaz, van Assche Véronique, Willems Arabelle, Huybrechts Sofie, Mast Bénédicte, van Olden Rudolf, Dangouloff Tamara, Servais Laurent

Abstract excerpt

Three new therapies for spinal muscular atrophy (SMA) have been approved by the United States Food and Drug Administration and the European Medicines Agency since 2016. Although these new therapies improve the quality of life of patients who are symptomatic at first treatment, administration before the onset of symptoms is significantly more effective. As a consequence, newborn screening programs have been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Belgium

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Management

Share to Muscular Atrophy, Spinal

Share to National Health Programs

Share to Outcome Assessment, Health Care

Share to Public Health Surveillance

Share to Referral and Consultation

Share to Workflow

Source

Open in PubMed Open full text

Identifiers

PMID: 34620959
DOI: 10.1038/s41598-021-99496-2
PMCID: PMC8497564

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium.PMID 34620959Read ↗

Results of the Hungarian Newborn Screening Pilot Program for Spinal Muscular AtrophySemantic proximity Read ↗

Establishment of a Pilot Newborn Screening Program for Spinal Muscular Atrophy in Saint-PetersburgSemantic proximity Read ↗

Establishment of a Pilot Newborn Screening Program for Spinal Muscular Atrophy in Saint PetersburgSemantic proximity Read ↗

Newborn screening facilitates early theranostics and improved spinal muscular atrophy outcome: five-year real-world evidence from TaiwanSemantic proximity Read ↗

Outcomes of A Pilot Newborn Screening Program for Spinal Muscular Atrophy in A Spanish RegionSemantic proximity Read ↗

Spinal muscular atrophy: from gene discovery to clinical trials.Semantic proximity Read ↗

Neonatal screening for spinal muscular atrophy: A pilot study in BrazilSemantic proximity Read ↗

Newborn Screening for SMA - Results After Two Years of a Large Pilot Project Semantic proximity Read ↗

Alberta Spinal Muscular Atrophy Newborn Screening—Results from Year 1 Pilot ProjectSemantic proximity Read ↗

New-Born Screening for Spinal Muscular Atrophy: Results of a Latvian Pilot StudySemantic proximity Read ↗

A Novel System for Spinal Muscular Atrophy Screening in Newborns: Japanese Pilot StudySemantic proximity Read ↗

Newborn and carrier screening for spinal muscular atrophy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.